Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: A secondary survey

Critical Care

Volumn 18, Issue 5, 2014, Pages

  Iba, Toshiaki ^a   Saitoh, Daizoh ^b   Wada, Hideo ^c   Asakura, Hidesaku ^d  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HEPARIN; RECOMBINANT THROMBOMODULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; FEMALE; HEALTH CARE SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT ASSESSMENT; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL; THROMBOCYTE COUNT; TREATMENT OUTCOME; CHEMICALLY INDUCED; CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR COAGULATION; HEMORRHAGE; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; SEPSIS; SURVIVAL RATE; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITHROMBINS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84907721570     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-014-0497-x     Document Type: Article

References (23)

1. Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre PF, Dhainaut JF. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit Care 2004, 8:R82-R90. 10.1186/cc2459, 15025782.
2. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010, 38:S26-S34. 10.1097/CCM.0b013e3181c98d21, 20083910.
3. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013, 369:840-851. 10.1056/NEJMra1208623, 23984731.
4. Levi M. Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. J Crit Care 2001, 16:167-177. 10.1053/jcrc.2001.30666, 11815902.
5. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient: High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286:1869-1878. 10.1001/jama.286.15.1869, 11597289.
6. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637. 10.1097/CCM.0b013e31827e83af, 23353941.
7. Wiedermann CJ, Kaneider NC. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagl Fibrinolysis 2006, 17:521-526. 10.1097/01.mbc.0000245302.18010.40.
8. Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way?. Crit Care Med 2012, 40:2704-2708. 10.1097/CCM.0b013e318258ff30, 22732284.
9. Gando S, Saitoh D, Ishikura H, Ueyama M, Otomo Y, Oda S, Kushimoto S, Tanjoh K, Mayumi T, Ikeda T, Iba T, Eguchi Y, Okamoto K, Ogura H, Koseki K, Sakamoto Y, Takayama Y, Shirai K, Takasu O, Inoue Y, Mashiko K, Tsubota T, Endo S. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care 2013, 17:R297. 10.1186/cc13163, 24342495.
10. Iba T, Nagaoka I, Boulat M. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Thromb Res 2013, 131:383-389. 10.1016/j.thromres.2013.03.012, 23566533.
11. Iba T. Harmonized guidance for DIC from the ISTH and the current status of anticoagulant therapy in Japan. J Thromb Haemost 2013, 11:2076-2078. 10.1111/jth.12344, 23819713.
12. Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, Koga S, Mayumi T, Koike K, Gando S, Kushimoto S, Seki Y, Madoiwa S, Maruyama I, Yoshioka A. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010, 125:6-11. 10.1016/j.thromres.2009.08.017, 19782389.
13. Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, Kim HK, Nielsen JD, Dempfle CE, Levi M, Toh CH. The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013, 11:761-767. 10.1111/jth.12155.
14. Iba T, Saito S, Wada H, Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: A prospective multicenter survey. Thromb Res 2012, 130:e129-e133. 10.1016/j.thromres.2012.03.021, 22542365.
15. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874.
16. Iba T, Gando S, Murata A, Kushimoto S, Saitoh D, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Ikeda T, Ishhikura H, Ueyama M, Ogura Y, Endo S, Shimazaki S. Predicting the severity of SIRS-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. J Trauma 2007, 63:1093-1098. 10.1097/01.ta.0000251420.41427.d3, 17993956.
17. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, Ohtomo Y, Okamoto K, Kushimoto S, Endo S, Shimazaki S. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med 2008, 36:145-150. 10.1097/01.CCM.0000295317.97245.2D, 18090367.
18. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, Ueyama M, Ogura H, Kushimoto S, Saitoh D, Endo S, Shimazaki S. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006, 34:625-631. 16521260.
19. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med 1998, 26:1793-1800. 10.1097/00003246-199811000-00016, 9824069.
20. Sawamura A, Gando S, Hayakawa M, Hoshino H, Kubota N, Sugano M. Effects of antithrombin III in patients with disseminated intravascular coagulation diagnosed by newly developed diagnostic criteria for critical illness. Clin Appl Thromb Hemost 2009, 15:561-566. 10.1177/1076029608323497, 18840625.
21. Gando S, Sawamura A, Hayakawa M, Hoshino H, Kubota N, Oshiro A. First day dynamic changes in antithrombin III activity after supplementation have a predictive value in critically ill patients. Am J Hematol 2006, 81:907-914. 10.1002/ajh.20696, 16924643.
22. Iba T, Nakarai E, Takayama T, Nakajima K, Sasaoka T, Ohno Y. Combination effect of antithrombin and recombinant human soluble thrombomodulin in an LPS induced rat sepsis model. Crit Care 2009, 13:R203-R209. 10.1186/cc8210, 20003418.
23. Iba T, Miki T, Hashiguchi N, Yamada A, Nagaoka I. Combination of antithrombin and recombinant thrombomodulin attenuates leukocyte-endothelial interaction and suppresses the increase of intrinsic DAMPs in endotoxemic rats. J Surg Res 2014, 187:581-586. 10.1016/j.jss.2013.10.058, 24296334.